William Blair Upgrades Terns Pharmaceuticals to Outperform After Strong TERN-701 Data

William Blair upgraded Terns Pharmaceuticals (TERN) to Outperform following impressive Phase 1 CARDINAL trial results of TERN-701 in chronic myeloid leukemia, showing a 75% overall major molecular response rate and strong safety profile.